

Anti-IL-23 Antibody (Guselkumab)

Introduction

Guselkumab is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. The binding K_d values of guselkumab to human and cynomolgus monkey IL-23 are 3.3 pM and 1.9 pM, respectively. Guselkumab inhibits the production of cytokines downstream of the IL-23 signaling pathway and can be used in the study of psoriatic arthritis.

Product parameters

Alternative Names	TREMFYA ONE-PRESS
Target Accession	Q9NPF7
Target	IL-23
CAS number	1350289-85-8
Molecular Weight	144.8 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL 23P40 His at 2 ug/mL can bind Anti-IL-23 Antibody (Guselkumab), EC50=0.009014 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

